Live from the NIH registry
Studies recruiting near Salem right now
Top 25 of 112 recruiting studies, sorted by proximity — each links to its official registry page
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
Gynecologic Cancers, Breast Cancer
Phase 1
Interventional 60 participants sought
Samaritan Pastega Regional Cancer Center — Corvallis, Oregon (27.4 mi)
· Sponsor: Oregon State University
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast Neoplasms, Neoplasm Metastasis
Phase 3
Interventional 800 participants sought
Good Samaritan Regional Medical Center — Corvallis, Oregon (27.4 mi)
· Sponsor: Eli Lilly and Company
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Sepsis, Acute Kidney Injury
Phase 2
Interventional 124 participants sought
Research Site — Corvallis, Oregon (27.4 mi)
· Sponsor: AstraZeneca
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: NRG Oncology
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Salem Hospital — Salem, Oregon (1.5 mi)
· Sponsor: SWOG Cancer Research Network
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 2,400 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Multiple conditions
Phase 2
Interventional 120 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 2, Phase 3
Interventional 316 participants sought
Oregon Oncology Specialists — Salem, Oregon (1.5 mi)
· Sponsor: Taiho Oncology, Inc.
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Prostate Cancer (Adenocarcinoma)
Phase 3
Interventional 830 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: Canadian Cancer Trials Group
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 626 participants sought
Oregon Oncology Specialists — Salem, Oregon (1.5 mi)
· Sponsor: Mirati Therapeutics Inc.
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 306 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Rectal Cancer
Phase 3
Interventional 250 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: Canadian Cancer Trials Group
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
Phase 3
Interventional 558 participants sought
Oregon Oncology Specialists — Salem, Oregon (1.5 mi)
· Sponsor: BioNTech SE
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2, Phase 3
Interventional 189 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: National Cancer Institute (NCI)
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Intestinal Neoplasms, Gastrointestinal Neoplasms
Phase 3
Interventional 800 participants sought
Oncology Associates of Oregon, P.C. — Albany, Oregon (20.2 mi)
· Sponsor: Pfizer
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 2
Interventional 112 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8
Phase 2
Interventional 44 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 1,100 participants sought
Salem Hospital — Salem, Oregon (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
Phase 3
Interventional 1,160 participants sought
Research Site — Salem, Oregon (1.5 mi)
· Sponsor: AstraZeneca
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 3
Interventional 94 participants sought
Providence Newberg Medical Center — Newberg, Oregon (26.2 mi)
· Sponsor: SWOG Cancer Research Network